Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb, GeneCentric To Collaborate on Opdivo Biomarker Study

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and GeneCentric Diagnostics are working together to explore whether GeneCentric's Cancer Subtype Platform can identify translational biomarkers for BMS's cancer immunotherapy Opdivo (nivolumab).

GeneCentric said it has also secured equity funding from BMS that will support the clinical development of its CSP and the build-out of its new laboratory in North Carolina's Research Triangle Park. It didn't disclose the amount of that investment, however.

According to GeneCentric, the CSP technology identifies biologic subtypes of cancer through an integrated analysis of tumor genomics.

"GeneCentric’s innovative approach to cancer biomarkers offers an opportunity to accelerate translational and exploratory biomarker research, with the potential to optimize assays that can better inform decisions about patient care and treatments,” BMS head of development for oncology Fouad Namouni said in a statement.

A University of North Carolina spinout, GeneCentric's first CSP-generated product was HistoPlus Lung Cancer, which is licensed to and offered by LabCorp.